title: Aggressive intervention of previable preterm premature rupture of membranes.
abstract: OBJECTIVE
  To assess the neonatal and maternal outcomes of pregnancy complicated by previable preterm premature rupture of membranes (PPROM).
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  Tertiary referral hospital. Sample. Forty-five women having aggressive intervention with antibiotics, amnioinfusion, cerclage and tocolysis.
  
  
  METHODS
  The hospital database between July 2001 and December 2009 was reviewed for women with singleton fetuses and PPROM before 23(+0) weeks of gestation. We analysed maternal and neonatal characteristics.
  
  
  METHODS
  Neonatal survival without major morbidity.
  
  
  RESULTS
  Thirty-eight infants were delivered alive and seven were stillborn. Ten infants died in the neonatal intensive care unit and one in the labor ward. Twenty-seven live-born infants survived to discharge from hospital. The survival rate of pregnancies with aggressive management was 60% (27 of 45); that of live-born infants was 71.1% (27 of 38). The median gestational age at PPROM and at delivery were significantly lower in the non-surviving group than the surviving group. Thirty-seven women (82.2%) had an amniotic neutrophil elastase level >0.15 μg/mL. Only four women (8.9%) developed clinical chorioamnionitis. Overall, 90.7% of the women showed histological evidence of chorioamnionitis. Eighty-three per cent of the surviving children had bronchopulmonary dysplasia. Nine infants had serious sequelae at a corrected age of one and a half years. Maternal complications were uncommon.
  
  
  CONCLUSIONS
  An aggressive treatment protocol for women with previable PPROM resulted in a high neonatal survival rate. Neonatal survival was associated with higher gestational age at delivery and with more frequent use of antenatal corticosteroids. The prognosis is still bad in PPROM before 22(+0) weeks of gestation.
authors.affiliation: Department of Obstetrics and Gynecology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Madoka
authors.initials: M
authors.lastname: Furuhashi
authors.forename: Kana
authors.initials: K
authors.lastname: Yoshida
authors.forename: Kaoru
authors.initials: K
authors.lastname: Ishikawa
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D023802:Cerclage, Cervical; D002821:Chorioamnionitis / Q000175:diagnosis / Q000188:drug therapy; D003131:Combined Modality Therapy; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D005328:Fetal Viability; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D012189:Retrospective Studies; D050497:Stillbirth; D015145:Tocolysis; D015149:Tocolytic Agents / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D015149:Tocolytic Agents